Elicit: TNF-Blockers: Infection and Cancer Risks
TNF-Blockers: Infection and Cancer Risks
Explore safety/mechanism links for TNF-blocker associated infections and malignancies
TNF-blockers have a clear mechanistic link to opportunistic infections through disruption of granuloma formation and immune surveillance (particularly for tuberculosis reactivation with monoclonal antibodies), but for malignancies, the evidence indicates that baseline inflammatory disease severity rather than immunosuppression from TNF-blockade itself drives most cancer risk, with only skin cancers showing consistent modest increases attributable to treatment.
Abstract
TNF-blockers demonstrate mechanistically coherent infection risks linked to TNF’s essential role in immune surveillance and host defense. While overall infection risk shows only modest increases (OR 1.18-1.20) that become non-significant when adjusted for exposure time (IRR 1.01), opportunistic infections show consistent 90% increased risk (OR 1.90) and tuberculosis risk increases 3- to 4-fold (OR 3.3-3.5). The mechanism centers on disruption of granuloma formation, explaining why tuberculosis occurs exclusively with monoclonal antibodies that completely neutralize TNF and why 72% of infliximab-associated granulomatous infections occur within 90 days, consistent with reactivation of latent infections rather than increased susceptibility to new pathogens. Agent-specific differences are substantial, with infliximab carrying 3.25-fold greater granulomatous infection risk than etanercept, reflecting mechanistic differences between complete TNF neutralization and partial receptor blockade.
For malignancies, competing biological mechanisms—TNF’s dual roles in suppressing tumors through apoptosis versus promoting cancer through chronic inflammation—generate heterogeneous findings that resolve upon careful examination. Long-term observational studies show no overall increased malignancy risk (OR 0.90-0.95) and no evidence that longer exposure increases risk, while short-term RCT meta-analyses finding elevated risk (OR 3.3) likely reflect detection bias given inadequate latency periods for cancer development. Skin cancers represent the most consistent signal (OR 1.45 for non-melanoma skin cancer), amplified by concomitant methotrexate (RR 1.97). For lymphomas, standardized incidence ratios of 1.8-6.0 in rheumatoid arthritis must be interpreted against 2-fold baseline elevation from systemic inflammation itself, and pooled estimates controlling for this confounding show no significant TNF-blocker effect (OR 1.11). The mechanistic framework suggests that baseline inflammatory disease severity, rather than immunosuppression per se, drives most malignancy risk in these populations.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.
Records from Elicit search
n = 200
Papers screened using: TNF-Blocker Intervention, Safety or Mechanistic Outcomes, Study Design, Adult Population, Clinical Indication, TNF-Specific Focus, Adequate Sample Size, Original Human Clinical Data
n = 200
Papers screened out
n = 190
Papers included for extraction
n = 10
Infection Outcomes
| Study | Any infection | Serious infections | Opportunistic infections | Tuberculosis | Other notable findings |
|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | OR 1.18 (95% CI 1.05-1.33) IRR 1.01 |
OR 0.70 (95% CI 0.40-1.21) IRR 0.59 |
Not measured | Not measured | Most common site: cellulitis |
| S. Minozzi et al., 2016 | OR 1.20 (95% CI 1.08-1.34) | OR 1.41 (95% CI 1.16-1.73) fixed effects | OR 0.94 (95% CI 0.33-2.64) fixed effects | OR 3.53 (95% CI 1.58-7.85) fixed effects | Risk increased with longer treatment duration |
| M. Muller et al., 2020 | Not reported | Not reported | Not reported | Not reported | Focus on malignancy outcomes |
| R. Pereira et al., 2017 | Not reported | IR 4.02/100 patient-years (95% CI 3.20-5.04) | Not reported | IR 0.28/100 patient-years (95% CI 0.12-0.66) | Most frequent site: gastrointestinal system |
| T. Bongartz et al., 2006 | Not reported | OR 2.0 (95% CI 1.3-3.1) NNH 59 |
Not reported | Not reported | Not specified |
| X. Mariette et al., 2011 | Not reported | Not reported | Not reported | Not reported | Study focused on malignancy outcomes |
| D. Solomon et al., 2012 | Not reported | Not reported | Not reported | Not reported | Study focused on malignancy outcomes |
| S. Bonovas et al., 2016 | OR 1.19 (95% CI 1.10-1.29) NNH 26 |
OR 0.89 (95% CI 0.71-1.12) OR 0.56 (95% CI 0.35-0.90) in low-risk bias studies |
OR 1.90 (95% CI 1.21-3.01) NNH 194 |
OR 2.04 (95% CI 0.71-5.89) | Specific pathogens: M. tuberculosis, JC virus... |
| R. Wallis et al., 2004 | Not reported | Not reported | 239/100,000 for infliximab vs 74/100,000 for etanercept | 144/100,000 for infliximab vs 35/100,000 for etanercept | 3.25-fold greater risk with infliximab vs etanercept |
Malignancy Outcomes
| Study | All-site malignancy | Non-melanoma skin cancer | Melanoma | Lymphoma | Other solid tumors |
|---|---|---|---|---|---|
| E. Dommasch et al., 2011 | OR 1.48 (95% CI 0.71-3.09) IRR 0.99 |
OR 1.33 (95% CI 0.58-3.04) 70.6% of all malignancies |
Not separately analyzed | OR 1.26 (95% CI 0.39-4.15) when NMSC excluded | Prostate and breast cancer reported |
| M. Muller et al., 2020 | 1.0% overall occurrence No significant association in 10/11 studies |
123/692 cases (17.8%) | Not specified | 106/692 cases (15.3%) One study found increased risk |
Digestive malignancies: 120/692 (17.3%) |
| R. Pereira et al., 2017 | IR 1.75/100 patient-years (95% CI 1.24-2.47) | Not specified | Not specified | Not specified | Not specified |
| T. Bongartz et al., 2006 | OR 3.3 (95% CI 1.2-9.1) NNH 154 |
Not separately analyzed | Not separately analyzed | Not separately analyzed | Dose-dependent relationship observed |
| X. Mariette et al., 2011 | OR 0.95 (95% CI 0.85-1.05) | OR 1.45 (95% CI 1.15-1.76) | OR 1.79 (95% CI 0.92-2.67) | OR 1.11 (95% CI 0.70-1.51) | No evidence longer exposure increases risk |
| D. Solomon et al., 2012 | Various estimates from different studies | OR 1.24 (95% CI 0.97-1.58) alone RR 1.97 (95% CI 1.51-2.58) with MTX |
Not specified | Risk estimates ranged 1.1-4.9 SIR 1.8-6.0 among TNFi users |
Hematologic malignancies SIR 2.0-4.1 |
| S. Bonovas et al., 2016 | OR 0.90 (95% CI 0.54-1.50) 0.45% treatment vs 0.54% placebo |
Not separately analyzed | Not separately analyzed | Not separately analyzed | Insufficient data on exposure/follow-up |
Mechanistic Insights
TNF plays a critical role in immune surveillance and host defense, creating a theoretical framework for both infection and malignancy risks with TNF inhibition. Multiple biological pathways have been proposed to explain the observed safety signals.
Risk Factors and Population Heterogeneity
Several patient and treatment characteristics modified infection and malignancy risk. Older age emerged as a risk factor for infections, though one meta-regression found no significant age association. Comorbid conditions including malnutrition and diabetes increased infection susceptibility.
Concomitant immunosuppressive therapy represented an important modifier, with evidence of synergistic effects when combining TNF-blockers with other systemic immunosuppressants. In psoriatic arthritis trials, 44.6% of patients received concomitant methotrexate, 5.5% other disease-modifying drugs, and 10.5% corticosteroids, while psoriasis trials generally excluded such combinations.